These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 17467880)

  • 1. Editorial comment on: botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
    Kocjancic E
    Eur Urol; 2007 Sep; 52(3):858-9. PubMed ID: 17467880
    [No Abstract]   [Full Text] [Related]  

  • 2. Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence.
    Schurch B; Denys P; Kozma CM; Reese PR; Slaton T; Barron RL
    Eur Urol; 2007 Sep; 52(3):850-8. PubMed ID: 17467889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of neurogenic incontinence with botulinum toxin A.
    Schurch B; Schmid DM; Stöhrer M
    N Engl J Med; 2000 Mar; 342(9):665. PubMed ID: 10702067
    [No Abstract]   [Full Text] [Related]  

  • 4. [Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
    de Sèze M; Ruffion A; Haab F; Chartier-Kastler E; Denys P; Game X; Karsenty G; Kerdraon J; Perrouin-Verbe B; Saussine C; Soler JM; Amarenco G
    Ann Readapt Med Phys; 2008 May; 51(4):315-21. PubMed ID: 18514963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Management of neurogenic bladder in children].
    Aubert D
    Prog Urol; 2008 Mar; 18(3):172. PubMed ID: 18472071
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele.
    Mall V; Glocker FX; Frankenschmidt A; Gordjani N; Heinen F; Brandis M; Korinthenberg R
    Pediatr Nephrol; 2001 Dec; 16(12):1161-2. PubMed ID: 11793122
    [No Abstract]   [Full Text] [Related]  

  • 8. [Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity].
    Perrouin-Verbe B; Ruffion A; Gamé X; Denys P; Kerdraon J; Karsenty G; de Sèze M; Haab F; Saussine C; Soler JM; Amarenco G; Chartier-Kastler E
    Prog Urol; 2009 Jun; 19(6):372-82. PubMed ID: 19467455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum A toxin in the treatment of neurogenic detrusor overactivity: a consolidated field of application.
    Giannantoni A; Mearini E; Del Zingaro M; Santaniello F; Porena M
    BJU Int; 2008 Jul; 102 Suppl 1():2-6. PubMed ID: 18665971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Novara G
    Eur Urol; 2008 Mar; 53(3):618-9. PubMed ID: 17804151
    [No Abstract]   [Full Text] [Related]  

  • 11. Reliability and validity of the Incontinence Quality of Life questionnaire in patients with neurogenic urinary incontinence.
    Schurch B; Denys P; Kozma CM; Reese PR; Slaton T; Barron R
    Arch Phys Med Rehabil; 2007 May; 88(5):646-52. PubMed ID: 17466735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury.
    Patki PS; Hamid R; Arumugam K; Shah PJ; Craggs M
    BJU Int; 2006 Jul; 98(1):77-82. PubMed ID: 16831148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin: a new dimension in the treatment of lower urinary tract dysfunction.
    Rajkumar GN; Conn IG
    Urology; 2004 Jul; 64(1):2-8. PubMed ID: 15245922
    [No Abstract]   [Full Text] [Related]  

  • 14. Editorial comment on: neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre.
    Wyndaele JJ
    Eur Urol; 2008 May; 53(5):1019-20. PubMed ID: 17950988
    [No Abstract]   [Full Text] [Related]  

  • 15. Refractory neurogenic detrusor overactivity.
    Cruz F; Silva C
    Int J Clin Pract Suppl; 2006 Dec; (151):22-6. PubMed ID: 17169007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Fowler CJ
    Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
    [No Abstract]   [Full Text] [Related]  

  • 17. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Schurch B
    Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
    [No Abstract]   [Full Text] [Related]  

  • 18. Botulinum toxin type A for the treatment of urinary tract dysfunction in neurological disorders.
    O'Leary M; Dierich M
    Urol Nurs; 2010; 30(4):228-34. PubMed ID: 20949807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 20. Study of botulinum toxin A in neurogenic bladder due to spina bifida in children.
    Deshpande AV; Sampang R; Smith GH
    ANZ J Surg; 2010 Apr; 80(4):250-3. PubMed ID: 20575951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.